Burden of hypertension
3 evidence topics · 28 sources
Summary: definitions, prevalence, and blood pressure control
The 2025 AHA/ACC guideline sets a blood pressure treatment goal of <130/80 mm Hg for all adults and defines resistant hypertension as blood pressure above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses, or blood pressure at goal on ≥4 medications. In NHANES data from August 2021 to August 2023, the prevalence of hypertension among US adults was 47.7%. Among adults with hypertension, 51.2% were taking medication to lower blood pressure and 20.7% had blood pressure controlled to less than 130/80 mm Hg, compared with 22.2% in 2017 to March 2020, a change that was not significant. ICER states that “more than 70% of adults with hypertension have not reached their goal blood pressure”. The US Million Hearts hypertension cascade estimates that 33.2 million adults already treated with antihypertensive medication may need a dose increase or additional medications to achieve blood pressure control, and that 18.8 million of this group have blood pressure ≥140/90 mm Hg.
Estimates of resistant hypertension vary with the definition, the blood pressure goal, and the data source. Under the <130/80 mm Hg goal, the 2025 AHA/ACC guideline estimates the prevalence of resistant hypertension at approximately 8.5% to 20% among hypertensive US adults. In NHANES data from 2003 to 2020, 1,939 of 24,579 adults with hypertension had apparent treatment-resistant hypertension, a prevalence of 6.41% (95% CI 5.97% to 6.88%) corresponding to a weighted total of 6,989,821 US adults; among adults on treatment, the prevalence decreased from 17.7% to 12.6% over the study period. ICER states that almost seven million Americans are estimated to have apparent treatment-resistant hypertension. In one cohort study, resistant hypertension was identified in 60,327 (12.8%) individuals with hypertension; uncontrolled resistant hypertension accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals. A poster hosted by the manufacturer, based on Optum Market Clarity data, estimated the prevalence of uncontrolled and resistant hypertension among adults with hypertension at 27.6% and 9.8%, respectively. Among 205,750 individuals with incident hypertension started on treatment, 1.9% developed resistant hypertension within a median 1.5 years (0.7 cases per 100 person-years). Worldwide, an estimated 1.4 billion adults aged 30 to 79 years had hypertension in 2024, and approximately 320 million (23%) had it under control.
Part of apparent resistance is pseudoresistance. A clinically significant white-coat effect may be present in 28% to 39% of individuals with apparent treatment-resistant hypertension by office measurement, and in a database in which 8295 individuals had resistant hypertension, 37.5% had white-coat resistance after ambulatory blood pressure monitoring. The 2025 AHA/ACC guideline states that primary aldosteronism occurs in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension. The manufacturer states that dysregulated aldosterone is a key factor in uncontrolled or resistant hypertension in approximately 30% of patients.
Summary: morbidity and mortality
In 2024, high blood pressure was a primary or contributing cause of 680,179 deaths in the United States. The US age-adjusted death rate attributable primarily to high blood pressure was 31.5 per 100,000 in 2022 and increased 63.2% from 2012 to 2022. In a pooled analysis of one million adults in 61 prospective studies, each 20 mm Hg difference in usual systolic blood pressure at ages 40 to 69 years was associated with more than a twofold difference in the stroke death rate and twofold differences in the death rates from ischemic heart disease and other vascular causes. In an individual participant data meta-analysis of 48 randomized trials, a 5 mm Hg reduction in systolic blood pressure reduced the risk of major cardiovascular events by about 10%; in a trial-level meta-analysis of 123 studies with 613,815 participants, each 10 mm Hg reduction in systolic blood pressure was associated with a 13% reduction in all-cause mortality.
The 2025 AHA/ACC guideline states that patients with resistant hypertension have “at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death” than adults with hypertension without resistance to treatment. Among 470,386 individuals with resistant or nonresistant hypertension, resistant hypertension compared with nonresistant hypertension had adjusted hazard ratios of 1.32 for end-stage renal disease, 1.24 for ischemic heart events, 1.46 for congestive heart failure, 1.14 for cerebrovascular accident, and 1.06 for all-cause mortality, and the risks of end-stage renal disease and cerebrovascular accident were 25% and 23% greater in uncontrolled than in controlled resistant hypertension. Among patients with incident treated hypertension followed for a median 3.8 years, cardiovascular events occurred in 18.0% of those with resistant hypertension and 13.5% of those without it (adjusted HR 1.47, 95% CI 1.33 to 1.62). In another study, resistant hypertension confirmed by ambulatory blood pressure monitoring was associated with higher all-cause mortality (HR 1.36) and cardiovascular mortality (HR 1.56) than controlled hypertension. In the REGARDS study, uncontrolled resistant hypertension was associated with a 2-fold increased risk of coronary heart disease compared with controlled resistant hypertension. The manufacturer states that hypertension persisting despite two or more medications carries 1.8 and 2.5 times greater mortality risk due to cardiovascular disease or stroke, respectively.
In a meta-analysis of 31 studies including 3838 participants with primary aldosteronism and 9284 participants with essential hypertension, primary aldosteronism was associated with an increased risk of stroke (OR 2.58), coronary artery disease (OR 1.77), atrial fibrillation (OR 3.52), and heart failure (OR 2.05).
Summary: humanistic and economic burden and limitations of current treatment
In pooled US Medical Expenditure Panel Survey data from 2000 to 2011, 2501 adults with hypertension (4.4%) met criteria for apparent treatment-resistant hypertension. Compared with non-resistant hypertension, they had lower mean physical component summary scores (35.8 and 43.2) and utility (0.68 and 0.74) and similar mental component summary scores (49.1 and 50.4); after multivariable adjustment, apparent treatment-resistant hypertension was associated with a 2.37 lower physical component summary score and a 0.02 lower utility. People living with hypertension told ICER that pill burden and additive copays for multiple medications can decrease adherence and persistence, and that insurance coverage barriers such as prior authorization and step therapy can cause people to abandon treatment.
Hypertension was associated with $2,759 in health care expenditures per person in the United States in 2019 and with estimated annual national health care expenditures of about $219.2 billion, including $32.5 billion in prescribed medication purchases. A review estimates that apparent resistant hypertension increases US health care expenditures by $11 billion to $18 billion per year over those associated with non-resistant hypertension. In linked US electronic medical record and claims data for 3,966 individuals with stage 3 to 4 chronic kidney disease using ≥3 antihypertensive medications, uncontrolled blood pressure (2,479 individuals) compared with controlled blood pressure (1,487 individuals) was associated with a higher risk of end-stage renal disease (HR 1.85) and inpatient hospitalization (rate ratio 1.35) and with higher total medical and pharmacy costs (mean difference $10,055 per patient per year). Out-of-pocket payments accounted for 16.6% of the $35.57 billion spent in the United States on treatment of hypertension in 2019, and in the 2017 National Health Interview Survey, 10.7% of 7,498 adults with self-reported hypertension reported cost-related medication nonadherence.
Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, and use rose from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that the rate of screening for primary aldosteronism in guideline-recommended individuals is <2% in the United States; among 269,010 Veterans with apparent treatment-resistant hypertension from 2000 to 2017, 4277 (1.6%) were tested for primary aldosteronism. A meta-analysis of 24 studies in people with uncontrolled blood pressure despite three or more antihypertensive medications of different classes estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%), and among 1348 participants in the UK and the Czech Republic, each additional antihypertensive medication was associated with an 85% and a 77% increase in biochemically confirmed nonadherence, respectively. With the aldosterone synthase inhibitor baxdrostat, hyperkalemia led to treatment discontinuation in 5.7% of participants in the pooled baxdrostat arm of the BaxHTN long-term extension, with safety data to 54 weeks.